SCHOFIELD, Wis., April 6, 2011 (GLOBE NEWSWIRE) -- PuraMed BioScience, Inc. (OTCQB:PMBS) announced today that the independent clinical study of LipiGesic™ M has been accepted for publication in a top-ranked medical journal.
"We are very pleased to have our clinical study accepted for publication in a top ranked medical journal and we plan to issue more information as it is made available," said PuraMed BioScience CEO Russell Mitchell.
About PuraMed BioScience, Inc.:
PuraMed BioScience, Inc. engages in the research, development and marketing of non-prescription medicinal and healthcare products. In addition to its leading product LipiGesic™ M, which provides acute relief from migraine headaches, the Company also has plans to launch LipiGesic™ PM that provides a remedy for insomnia and other sleep disorders as well as LipiGesic™ H for tension-type headaches. For more information on PuraMed, visit the Company website at , join the Company's group page on Facebook by searching "PuraMed BioScience" and follow the Company on Twitter at .
Forward Looking Statements: This news release contains forward-looking statements regarding PuraMed BioScience and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.
CONTACT: Russell Mitchell, Chairman and CEO PuraMed BioScience, Inc. 715-359-6373 www.PuraMedBioScience.com Investor Relations: Investor Awareness, Inc. Tony Schor or James Foy, 847-945-2222 www.investorawareness.com Media Contact: North Shore Public Relations, Inc. Renae Placinski, 847-945-4505 www.northshorepr.com